BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36348577)

  • 1. Regional location of lymph node metastases predicts survival in patients with
    Wang ZP; Chen JR; Zhao JG; Zhu S; Zhang XM; Liang JY; He B; Ni YC; Sun GX; Shen PF; Zeng H
    Asian J Androl; 2023; 25(4):462-467. PubMed ID: 36348577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
    Heesterman BL; van der Poel HG; Schoots IG; Mehra N; Aben KKH
    BJU Int; 2022 Aug; 130(2):217-225. PubMed ID: 34741789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of non-regional lymph node metastases accurately revealed on
    Jiang Z; Fan J; Gan C; Dong X; Gao G; Wang Z; He D; Li L; Duan X; Wu K
    EJNMMI Res; 2023 Jul; 13(1):64. PubMed ID: 37410264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of nonregional lymph node metastasis as a prognostic factor in metastatic prostate cancer patients.
    Cho S; Kang SG; Tae BS; Cheon J
    Korean J Urol; 2012 Oct; 53(10):673-9. PubMed ID: 23136626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
    Ali A; Hoyle A; Mistry H; Clarke NW
    BJU Int; 2019 Jan; 123(1):65-73. PubMed ID: 29777564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
    Rii J; Sakamoto S; Yamada Y; Takeshita N; Yamamoto S; Sazuka T; Imamura Y; Nakamura K; Komiya A; Komaru A; Fukasawa S; Nakatsu H; Akakura K; Ichikawa T
    Prostate; 2020 Aug; 80(11):850-858. PubMed ID: 32501559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites.
    Tappero S; Piccinelli ML; Incesu RB; Cano Garcia C; Barletta F; Morra S; Scheipner L; Baudo A; Tian Z; Parodi S; Dell'Oglio P; de Cobelli O; Graefen M; Chun FKH; Briganti A; Longo N; Ahyai S; Carmignani L; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
    Clin Genitourin Cancer; 2024 Apr; 22(2):47-55.e2. PubMed ID: 37690970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
    Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
    Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
    Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery on Metastatic Foci is a Better Strategy for Stage IV Breast Cancer Patients with only Nonregional Lymph Node Metastasis.
    Jiao Y; Guo X; Wu H; Lv Q
    Adv Ther; 2023 Jul; 40(7):3247-3262. PubMed ID: 37270436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and oncologic findings of extraprostatic extension on needle biopsy in
    Chen JR; Zhao JG; Zhu S; Zhang MN; Chen N; Liu JD; Sun GX; Shen PF; Zeng H
    Asian J Androl; 2020; 22(4):427-431. PubMed ID: 31424026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of patients with prostate carcinoma presenting as nonregional lymph node metastases.
    Furuya Y; Akakura K; Akimoto S; Ito H
    Urol Int; 1998 Oct; 61(1):17-21. PubMed ID: 9792977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
    Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
    Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with De Novo Metastatic Prostate Cancer.
    Zhao J; Liu J; Sun G; Zhang M; Chen J; Shen P; Liu Z; Liao B; Zhang X; Gong J; Chen N; Zeng H;
    J Urol; 2019 Apr; 201(4):759-768. PubMed ID: 30652989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
    Pond GR; Sonpavde G; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
    Eur Urol; 2014 Jan; 65(1):3-6. PubMed ID: 24120464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer.
    Tsuchida K; Inaba K; Kashihara T; Murakami N; Okuma K; Takahashi K; Igaki H; Nakayama Y; Maejima A; Shinoda Y; Matsui Y; Komiyama M; Fujimoto H; Ito Y; Sumi M; Nakano T; Itami J
    Cancer Med; 2020 Sep; 9(18):6629-6637. PubMed ID: 32750234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.